Veradermics (MANE) Shares Outstanding (2024 - 2026)
Veradermics posted quarterly Shares Outstanding of $37.3 million for Q1 2026, up 4966.99% year-on-year from $736933.0 in Q1 2025, and up 4880.3% on a QoQ basis from $749760.0 in Q4 2025.
Veradermics (MANE) has 3 years of Shares Outstanding data on file, last reported at $37.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding rose 4966.99% year-over-year to $37.3 million; the trailing twelve-month figure through Mar 2026 stood at $37.3 million (up 4966.99% YoY), and the FY2025 full-year result was $749760.0, up 1.74% from the prior year.
- Shares Outstanding for Q1 2026 stood at $37.3 million, up from $749760.0 in the prior quarter.
- Across five years, Shares Outstanding topped out at $37.3 million in Q1 2026 and bottomed at $736933.0 in Q4 2024.
- The 3-year median for Shares Outstanding is $743346.5 (2024), against an average of $9.9 million.
- The widest annual swing landed in 2025, when Shares Outstanding advanced 1.74%; it then surged 4966.99% in 2026.
- A 3-year view of Shares Outstanding shows it stood at $736933.0 in 2024, then rose by 1.74% to $749760.0 in 2025, then soared by 4880.3% to $37.3 million in 2026.
- The last three Shares Outstanding figures came in at $37.3 million (Q1 2026), $749760.0 (Q4 2025), and $736933.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 5.21 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 56.35 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 91.57 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.16 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.80 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 133.44 Mn |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | 37.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Mar 31, 2026 | 37.34 Mn |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Dec 31, 2025 | 749,760.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Mar 31, 2025 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |